ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
LOH and Testosterone Therapy – A Summary of Guidelines from the AUA and the EAU
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 141926" data-attributes="member: 13851"><p><strong>Late-onset Hypogonadism and Testosterone Therapy – A Summary of Guidelines from the American Urological Association and the European Association of Urology (2019)</strong></p><p><span style="color: rgb(184, 49, 47)"><em>Mikkel Fode , Andrea Salonia , Suks Minhas , Arthur L. Burnett , Alan W. Shindel </em></span></p><p></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>Abstract</strong></span></p><p></p><p><em>Men with low serum testosterone and symptoms of androgen deficiency may be diagnosed with testosterone deficiency. This condition is associated with metabolic syndrome and cardiovascular disease. <strong>The benefits (eg, improvement in sexual function) and risks (eg, prostate cancer and cardiovascular disease) of testosterone therapy are controversial. </strong>The American Urological Association and European Association of Urology guidelines on testosterone therapy differ on several points of management, likely reflecting the ambiguities surrounding testosterone therapy in practice. <strong><span style="color: rgb(184, 49, 47)">This paper summarizes both guidelines with a focus on the differences between the two sets of guidelines. </span></strong></em></p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Patient summary</span></strong></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong><em>The benefits and risks of testosterone therapy are controversial,</em></strong></span><em><strong> as reflected in the European Association of Urology and American Urological Association guidelines<span style="color: rgb(184, 49, 47)"> that differ on several points of management.</span></strong></em></p><p></p><p></p><p></p><p></p><p><strong>7. Goals for future research </strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)"><em>Discrepancies between the guidelines reflect limited and conflicting evidence throughout the literature. </em></span></strong><em>Future studies should be designed with the intent of defining biochemical thresholds and elucidating the true clinical relevance of free T. Exploration of the effects of TT on overall QOL and identification of men with sexual dysfunction who will benefit from TT are other priorities. </em><strong><em>Further data on (1) the overall long-term effects of TT, and (2) long-term effects on cardiovascular health and PCA risk are required, with <span style="color: rgb(184, 49, 47)">particular emphasis on high-quality prospective/randomized clinical studies.</span> </em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 141926, member: 13851"] [B]Late-onset Hypogonadism and Testosterone Therapy – A Summary of Guidelines from the American Urological Association and the European Association of Urology (2019)[/B] [COLOR=rgb(184, 49, 47)][I]Mikkel Fode , Andrea Salonia , Suks Minhas , Arthur L. Burnett , Alan W. Shindel [/I][/COLOR] [COLOR=rgb(0, 0, 0)][B]Abstract[/B][/COLOR] [I]Men with low serum testosterone and symptoms of androgen deficiency may be diagnosed with testosterone deficiency. This condition is associated with metabolic syndrome and cardiovascular disease. [B]The benefits (eg, improvement in sexual function) and risks (eg, prostate cancer and cardiovascular disease) of testosterone therapy are controversial. [/B]The American Urological Association and European Association of Urology guidelines on testosterone therapy differ on several points of management, likely reflecting the ambiguities surrounding testosterone therapy in practice. [B][COLOR=rgb(184, 49, 47)]This paper summarizes both guidelines with a focus on the differences between the two sets of guidelines. [/COLOR][/B][/I] [B][COLOR=rgb(184, 49, 47)]Patient summary[/COLOR][/B] [COLOR=rgb(0, 0, 0)][B][I]The benefits and risks of testosterone therapy are controversial,[/I][/B][/COLOR][I][B] as reflected in the European Association of Urology and American Urological Association guidelines[COLOR=rgb(184, 49, 47)] that differ on several points of management.[/COLOR][/B][/I] [B]7. Goals for future research [COLOR=rgb(184, 49, 47)][I]Discrepancies between the guidelines reflect limited and conflicting evidence throughout the literature. [/I][/COLOR][/B][I]Future studies should be designed with the intent of defining biochemical thresholds and elucidating the true clinical relevance of free T. Exploration of the effects of TT on overall QOL and identification of men with sexual dysfunction who will benefit from TT are other priorities. [/I][B][I]Further data on (1) the overall long-term effects of TT, and (2) long-term effects on cardiovascular health and PCA risk are required, with [COLOR=rgb(184, 49, 47)]particular emphasis on high-quality prospective/randomized clinical studies.[/COLOR] [/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
LOH and Testosterone Therapy – A Summary of Guidelines from the AUA and the EAU
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top